Skip to content

Cardiovascular Disease (CVD) in Haemophilia

Cardiovascular Disease in Adult Haemophilia Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01303900
Enrollment
750
Registered
2011-02-25
Start date
2009-01-31
Completion date
Unknown
Last updated
2011-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease, Haemophilia

Keywords

Haemophilia, Cardiovascular disease, Cardiovascular disease risk factors, Prospective, QRISK2, Hypertension, Hypercholesterolaemia, Diabetes, Obesity

Brief summary

Life expectancy of hemophilia patients has improved considerably during the past decades and is approaching that of the general population. Hemophilia patients are therefore likely to be confronted with age-related disorders in addition to their primary illness and related diseases. Little is known about the occurrence of age-related co-morbidity, especially cardiovascular disease (CVD), in these patients. Low clotting factor levels are hypothesized to protect against both atherosclerosis and thrombus formation, resulting in a reduced risk of ischemic CVD. CVD mortality has been reported to be lower in haemophilia patients than in the general population, but data on non-fatal CVD are lacking, and no adjustment for CVD risk factors has been made so far. The aim of our study is to assess the occurrence of CVD and its risk factors in a large cohort of haemophilia patients. In this prospective multicenter cohort study in a group of 700-800 male patients with haemophilia A or B aged 30 years or older from The Netherlands and the UK, data on CVD history and CVD risk factors will be collected at baseline and compared with the general age-matched male population. Overall QRISK2 cardiovascular risk scores will be calculated and also compared with the general population. During a follow-up period of 5 and 10 years the occurrence of CVD events will be recorded and compared with the expected occurrence based on the QRISK2 scores and with data from the general population.

Interventions

None listed

Sponsors

UMC Utrecht
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
MALE
Age
30 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Haemophilia A or B (mild, moderate or severe) * Male gender * Age 30 years or older * Treated at participating haemophilia treatment center

Exclusion criteria

* No specific

Design outcomes

Primary

MeasureTime frame
Ischemic cardiovascular diseaseAfter 5 and 10 years
Cardiovascular disease risk factorsAt baseline

Secondary

MeasureTime frame
Association between clotting factor concentrate administration and cardiovascular events5-10 years

Countries

Netherlands, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026